GlassScriptPhysician profile
Farinaz Farrahi
NPI 1174661227
$2,457.35
in general payments reported to CMS, 2019-2025
28 companies · $617 in 2025
The $617 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $51.66 · 2021: $28.33 · 2022: $322 · 2023: $709 · 2024: $502 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.04 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $730.00 | 2019-2025 | Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $223.74 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.32 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $189.89 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $188.88 | 2022-2025 | Nucala, Shingrix, Arexvy |
| Amgen INC. | $121.05 | 2023-2025 | Tezspire |
| Novo Nordisk INC | $94.74 | 2024-2025 | Wegovy |
| Genzyme Corporation | $70.54 | 2023 | |
| Xeris Pharmaceuticals, INC. | $69.37 | 2023-2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $63.25 | 2019-2020 | |
| Mannkind Corporation | $58.58 | 2022-2023 | Afrezza |
| Radius Health, INC. | $57.01 | 2021-2022 | |
| Lilly USA, LLC | $52.71 | 2025 | Zepbound, Mounjaro |
| Ionis Pharmaceuticals, INC. | $29.88 | 2025 | Dawnzera |
| Bayer Healthcare Pharmaceuticals INC. | $29.47 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $29.34 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $29.16 | 2022 | |
| Shire North American Group INC | $23.69 | 2019 | |
| Grifols USA, LLC | $21.43 | 2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.08 | 2024 | |
| Tandem Diabetes Care, INC. | $17.85 | 2022 | |
| Exact Sciences Corporation | $17.76 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $16.74 | 2023 | Onzetra Xsail, Contrave |
| Csl Behring | $16.48 | 2019 | |
| Pfizer INC. | $15.27 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.80 | 2019 | |
| Halozyme INC | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farinaz Farrahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.